-
Aug 27, 2024 | 
nature.com | Meera Mohan
CORRESPONDENCE 27 August 2024 The Wayanad landslides of 30 July in the Indian state of Kerala caused huge disruption and are thought to have claimed up to 500 lives (see go.nature.com/3yte3yv). They should be a wake-up call to change current practices of landslide hazard mapping.
-
Apr 14, 2024 | 
onlinelibrary.wiley.com | Meera Mohan |Carolina Schinke |Ashby TC
As clinical outcomes and therapeutic options in multiple myeloma (MM) continue to improve, there is a growing interest in stratifying newly diagnosed MM patients to further tailor treatment based on disease risk.
-
Feb 14, 2024 | 
nature.com | Meera Mohan |Aniko Szabo |Samer Al Hadidi |Nirav Shah |Frits van Rhee |Mehdi Hamadani | +1 more
AbstractPersistent Immune Effector Cell Associated Hematotoxicity (ICAHT) is a significant side effect of BCMA CAR T-Cell therapy in patients with relapsed multiple myeloma (MM). The use of stem cell boosts in ICAHT has been described, however studies have been limited by small patient numbers and short follow up.
-
Jan 24, 2024 | 
nature.com | Timothy Schmidt |Rafael Fonseca |Rajshekhar Chakraborty |Meera Mohan |Luciano Costa |Douglas Sborov | +1 more
AbstractExtra copies of chromosome 1q21 (+1q: gain = 3 copies, amp >= 4 copies) are associated with worse outcomes in multiple myeloma (MM). This systematic review assesses the current reporting trends of +1q, the efficacy of existing regimens on +1q, and its prognostic implications in MM randomized controlled trials (RCTs). Pubmed, Embase and Cochrane Registry of RCTs were searched from January 2012 to December 2022. Only MM RCTs were included.
-
Nov 26, 2023 | 
nature.com | Rajshekhar Chakraborty |Meera Mohan
To the editor:Bispecific antibodies (bsAbs) targeting B-cell maturation antigen (BCMA) have transformed the landscape of relapsed/refractory (R/R) multiple myeloma, with single-agent response rates of 60–70% in patients who have undergone extensive prior treatments [1,2,3]. To date, two BCMA-targeting bsAbs have received accelerated approval by the Food and Drug Administration in R/R myeloma-teclistamab and elranatamab.
-
Jun 7, 2023 | 
onlinelibrary.wiley.com | Meera Mohan |Rajshekhar Chakraborty |Columbia USA |Susan Bal
MECHANISMS OF IMMUNOSUPPRESSION Hypogammaglobulinemia, an on-target off-tumour toxicity of BsAb and CAR T-cell therapies in MM, is an important driver of increased infection risk. The antigens, BCMA,23 GPRC5D24 and FCRH515 are expressed on almost all normal plasma cells, which makes it extremely difficult to avoid hypogammaglobulinemia when using highly effective therapies that target one or more of these antigens.
-
May 19, 2023 | 
onclive.com | Meera Mohan
Meera Mohan, MD, MS, FACP, assistant professor, hematology, medical oncology, Froedtert & The Medical College of Wisconsin, discusses the significance of CAR T-cell therapies and bispecific antibodies in patients with relapsed/refractory multiple myeloma. CAR T-cell therapies and bispecific antibodies have expanded the treatment arsenal for patients with relapsed/refractory multiple myeloma, Mohan says.
-
May 10, 2023 | 
onclive.com | Meera Mohan
Meera Mohan, MD, MS, FACP, assistant professor, Department of Medicine, Division of Hematology, Medical College of Wisconsin, medical oncologist, Froedtert Hospital, discusses adverse effects (AEs) associated with CAR T-cell therapy in relapsed/refractory multiple myeloma.
-
May 4, 2023 | 
onclive.com | Meera Mohan
Meera Mohan, MD, MS, FACP, assistant professor, Department of Medicine, Division of Hematology and, Medical College of Wisconsin, medical oncologist, Froedtert Hospital, discusses the toxicities associated with T-cell–directed therapies in relapsed/refractory multiple myeloma. The emergence of the CAR T-cell therapies and bispecific antibodies have led to improved responses in later lines of treatment for patients with relapsed/refractory multiple myeloma.
